Best Quality 99% Dexmedetomidine hydrochloride CAS:145108-58-3 From Hyperchem
TDS 3 Inquiries
1374853-91-4
Pharmaceutical Grade
99.9%
Hangzhou
HyperChem
1g/bag, 20g/bag, 50g/bags or other quantities
2027-04-30
Pharmaceuticals,Peptide,Cosmetics,Nutritional Supplements
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferencePembrolizumab (brand name Keytruda) is a PD-1 inhibitor developed by Merck & Co., Ltd. It was first approved by the FDA in 2014 for the treatment of certain patients with metastatic melanoma. In 2015, the FDA approved Keytruda (pembrolizumab) for advanced non-small cell lung cancer. Subsequently, pembrolizumab was approved for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma, as first-line treatment for certain metastatic non-small cell lung cancer patients, Hodgkin's lymphoma (cHL), and certain locally advanced or metastatic urothelial carcinoma patients. In 2025, the FDA approved pembrolizumab as neoadjuvant therapy for PD-L1+ resectable locally advanced head and neck squamous cell carcinoma, and continued as adjuvant therapy in combination with radiotherapy.CertificatesBasic Info
-
Product Name:
Pembrolizumab
Other Name:Pembrolizumab;Pembrolizumab (anti-PD-1);PEMBROLIMUMAB PD-1 1374853-91-4;Pembrolizumab 25mg/ml;PembrolizumabQ: What is Pembrolizumab Q: What is the CAS Number of Pembrolizumab Q: What is the storage condition of Pembrolizumab Q: What are the applications of Pembrolizumab;Research Grade Pembrolizumab(DHH02202);MK-3475;Research Grade Pembrolizumab
CAS No.:1374853-91-4
Molecular Weight:0
EC Number:807-012-2
Color/Form:Colorless to light yellow
Categories:
Characteristics-
Critical Temperature & Pressure:
Store at -80°C
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Pharmaceuticals,Peptide,Cosmetics,Nutritional Supplements
-
Location:
Rm. 803, Tower 4, LOFT49 Creative City Pioneer Zone, No.88 Jiru Rd. Gongshu Dist., Hangzhou, 310015 ZJ, China
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
10
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
11-50
-
Year of Establishment:
2013
-
Certifications:
Certification Report by Bureau Veritas
-
-
Inquiry History3 Inquiries
Country Product Purchase Quantity Date Posted
Netherlands
High quality Pembrolimumab/ supplier with competitive price in stock-Rechems Cas No: 1374853-91-4
1 KG Jan 2, 2025
Netherlands
pembrolizumab
1 KG Jan 2, 2025
South Korea
pembrolizumab
10 G Nov 28, 2024 Post an enquiry for this product
